The CD34⁺ Cell Dose Matters in Hematopoietic Stem Cell Transplantation with Peripheral Blood Stem Cells from Sibling Donors.

Clinical Hematology International Pub Date : 2020-03-04 eCollection Date: 2020-06-01 DOI:10.2991/chi.d.200221.001

M Remberger, B Grønvold, M Ali, J Mattsson, T Egeland, K U Lundin, A Myhre, I Abrahamsen, D Heldal, I Dybedal, G E Tjønnfjord, T Gedde-Dahl, Y Fløisand

{"title":"The CD34+ Cell Dose Matters in Hematopoietic Stem Cell Transplantation with Peripheral Blood Stem Cells from Sibling Donors.","authors":"M Remberger, B Grønvold, M Ali, J Mattsson, T Egeland, K U Lundin, A Myhre, I Abrahamsen, D Heldal, I Dybedal, G E Tjønnfjord, T Gedde-Dahl, Y Fløisand","doi":"10.2991/chi.d.200221.001","DOIUrl":null,"url":null,"abstract":"The effect of CD34+ cell dose in allogeneic hematopoietic stem cell transplantation (HSCT) on overall survival (OS) and incidence of acute and chronic graft-versus-host disease (GvHD) has not been established and few studies have been performed. Our single center analysis included 189 patients with hematological malignancies who received peripheral blood stem cell (PBSC) grafts from sibling donors. Myeloablative conditioning was used in 88 cases and 101 received reduced intensity conditioning. The median CD34+ cell dose was 5.6 × 106/kg (0.6-17.0). In the multivariate analysis, a CD34 cell dose of 6-7 × 106/kg was associated with better OS and lower transplant-related mortality (TRM), while a dose of <5 × 106/kg led to increased relapse and reduced chronic GVHD (cGVHD). A high CD34 cell-dose (>6.5 × 106/kg) correlated with less acute GVHD (aGVHD) II-IV. We conclude that the CD34 cell dose has an impact on the outcome of HSCT from sibling donor PBSCs.","PeriodicalId":10368,"journal":{"name":"Clinical Hematology International","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2020-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/87/3b/CHI-2-2-74.PMC8432346.pdf","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Hematology International","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2991/chi.d.200221.001","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/6/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 4

Abstract

The effect of CD34⁺ cell dose in allogeneic hematopoietic stem cell transplantation (HSCT) on overall survival (OS) and incidence of acute and chronic graft-versus-host disease (GvHD) has not been established and few studies have been performed. Our single center analysis included 189 patients with hematological malignancies who received peripheral blood stem cell (PBSC) grafts from sibling donors. Myeloablative conditioning was used in 88 cases and 101 received reduced intensity conditioning. The median CD34⁺ cell dose was 5.6 × 10⁶/kg (0.6-17.0). In the multivariate analysis, a CD34 cell dose of 6-7 × 10⁶/kg was associated with better OS and lower transplant-related mortality (TRM), while a dose of <5 × 10⁶/kg led to increased relapse and reduced chronic GVHD (cGVHD). A high CD34 cell-dose (>6.5 × 10⁶/kg) correlated with less acute GVHD (aGVHD) II-IV. We conclude that the CD34 cell dose has an impact on the outcome of HSCT from sibling donor PBSCs.

Abstract Image

查看原文本刊更多论文

CD34+细胞剂量对兄弟姐妹外周血干细胞造血干细胞移植的影响

同种异体造血干细胞移植(HSCT)中CD34+细胞剂量对总生存期(OS)和急性和慢性移植物抗宿主病(GvHD)发病率的影响尚未确定，相关研究也很少。我们的单中心分析纳入了189例接受兄弟姐妹供体外周血干细胞(PBSC)移植的血液恶性肿瘤患者。88例采用清髓调节，101例采用低强度调节。中位CD34+细胞剂量为5.6 × 106/kg(0.6-17.0)。在多变量分析中，CD34细胞剂量为6-7 × 106/kg与更好的OS和更低的移植相关死亡率(TRM)相关，而剂量为6/kg导致复发增加和慢性GVHD (cGVHD)减少。高CD34细胞剂量(>6.5 × 106/kg)与较低的急性GVHD (aGVHD) II-IV相关。我们得出结论，CD34细胞剂量对来自兄弟姐妹供体PBSCs的HSCT结果有影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Hematology International

自引率

0.00%

发文量